Cyteir Therapeutics, Inc. launches an IPO.

IPO of Cyteir Therapeutics, Inc. will take place on June, 17 2021.

Cyteir Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. These drugs inhibit DNA, cure the damage and ruin the cancer cells with the therapy. It took only 3 years for the company to pass from the discovery of its product CYT-0851 to the clinical trials. In 2021 Cyteir Therapeutics is planning to appoint the optimal development plan to ratificate CYT-0851 as a monotherapy for the late stages cure of some solid tumors. 

The listed IPO bookrunners are JP Morgan, Morgan Stanley, BofA Securities и Wedbush PacGrow.